Prevest Denpro Ltd

BSE: 543363

₹ 378.95+0.37%refreshed 26 Oct, 03:30 pm ISTMarket cap: ₹ 455 crWebsite: www.prevestdenpro.comUpdated: 27 Oct 2026

About

Prevest DenPro makes dental materials and oral care products, including restorative, endodontic, prosthetic, orthodontic and preventive care products as well as dental equipment. It makes them at a plant in Samba, Jammu & Kashmir, with an installed capacity of more than 200 MT per annum. Consolidated revenue from operations was Rs 71.81 crore in FY26, and more than 60% of revenue comes from exports to more than 90 countries. The Ministry of Commerce has recognised the company as a Star Export House.^[1][2]

Business and products

The company reports a single segment, dental materials, so it publishes no segment breakdown (FY26).^[1]
Restorative and endodontic products remained the main contributors to revenue in FY26.^[1]
Its strategic brands include the Rotoflex endodontic file system, Oradox Oral Care and ViroSafe disinfectants (FY26).^[1]
About 55-60% of revenue came from the top 20 products in FY25.^[3]
Sales of 3D printers, sold under the Omni brand launched in November 2025, grew 162% in FY26. Sales of 3D resins grew 40.5%.^[4]
The disinfectant business started selling commercially during H1 FY26.^[5][4]
Oradox oral care sales fell 2% in FY26 because exports to the US and Dubai were disrupted. Oradox brought in about INR 50 lakhs in FY25.^[4][3]

Manufacturing and capacity

The plant at EPIP Kartholi, Bari Brahmana, Samba, Jammu & Kashmir has an installed capacity of more than 200 MT per annum (FY26).^[1]
Traditional lines ran at about 67-68% utilisation in FY26. Management said full use of installed capacity would give a turnover of about INR 125 crores.^[4]
New lines, covering digital dentistry, resins, disinfectants and oral health, ran at about 18-20% utilisation in FY26.^[4]
The company now makes selected critical raw materials in-house to rely less on imports (FY26).^[1]
It has scaled up production of hydroxyapatite, tricalcium phosphate, bioglass and mineral trioxide aggregate and plans to sell them to other manufacturers (FY25).^[3]

Exports and markets

Exports grew 17.58% and domestic sales grew 9% in FY26. In FY25 exports grew 10.02% and domestic sales grew 12.54%.^[4][3]
In H1 FY26, export revenue was ₹20.72 Cr, up 24.30% from ₹16.67 Cr. Domestic revenue was ₹13.23 Cr, up 5.08%.^[5]
US business grew 37.58% in FY26, compared with about 14% growth in FY25.^[4][3]
Asia made up 49% of revenue and Europe 27% in FY25.^[3]
The company exported to 90-92 countries in FY26.^[4]

Customers and distribution

The network included 60+ dealers in India and 90+ overseas agents in H1 FY26.^[5]
The company makes products as an OEM for 3-4 companies and expects to add 2 more large companies over the next 2 years (as of FY26).^[4]
Exhibitions in the US under the Axiodent name are bringing in private-label orders (FY26).^[4]
The e-commerce platform Prevest Direct was launched in late 2023.^[6]
About 16 educational and clinical training programmes were held for dental professionals in FY26.^[1]

Subsidiaries

The subsidiaries are Axiodent Inc. (USA), Prevest Denpro Gulf General Trading L.L.C (Dubai) and Denviso Biomed Limited (India) (FY26).^[1]
The UAE subsidiary was set up in February 2026 and has 2 sales managers. Its start was delayed by the Middle East conflict, and online sales are planned for about July 2026.^[4]

Approvals and R&D

The company holds USFDA clearances for dental cements, cavity liners and root canal sealers and is registered with the Saudi FDA (FY26).^[1]
The plant is ISO 13485:2016 certified, its quality system is MDSAP-compliant and audited by TÜV SÜD, and its products carry CE marking (FY26).^[1]
The Prevest Research Institute is a DSIR-recognised R&D centre. The company has an MoU with IIT Kanpur on biomaterials and works with more than 20 dental colleges (FY26).^[1]
Three indigenously developed products were launched in FY25: Crysta Axis, Caries Cure SDF and Crysta LC RMGI.^[3]
Products in development include CariCure SDF 38%, OSTOGLASS, OSTOCAS and NeoCas cement (FY26).^[1]
The company holds test licences for 4 new products: caries removal agents, endodontic irrigants, self-etching resins and periodontal gels (FY26).^[4]

Plans

The company plans a fully indigenous 3D printer by 2028, developed in-house and with partners.^[4]
Management expects 2-3 new Oradox oral care products in FY27.^[4]

Recent developments

At its FY25 AGM, the company sought members' approval to move its shares from the BSE SME Platform to the BSE Main Board.^[7]
Revenue from operations grew 2.63% year on year to INR 18.94 crores in Q4 FY26. Management linked the weak quarter to geopolitical tensions and shipping disruptions.^[4]

Market Cap

₹455 Cr

High / Low

₹550 / 318

Stock P/E

22.1

Price / Book

3.6

Book Value

₹104

EPS

₹17.1

No. of Shares

1.2 Cr

ROCE

23.9%

ROE

17.8%

OPM

36.0%

Debt / Equity

0.00

Sales

₹72 Cr

Net Profit

₹20 Cr

Promoter holding

73.6%

Loading chart…

Signal history

AI Deep Dive

The analysis Screener can't give you

Our models read the latest earnings call, annual report, and financials end-to-end - then grade management, value the business, and flag the risks. Unlock all of it for this company:

Verdict
The headline call - descriptive label, conviction, and the synthesis behind it.
Valuation
Guidance-anchored P&L bridge - worst / average / best multiple cases.
Walk the talk
Did management deliver on past guidance? A commitment-by-commitment scorecard.
Red flags
Forensic and governance risk pointers, severity-ranked.
Balance sheet
Solvency and earnings-quality score.
Concall briefs
Quarter-by-quarter earnings-call briefs - what changed and why.

₹49 unlocks this company for 90 days, ₹299 for a full year - bundles bring it lower. Built on public disclosures - educational, not investment advice.

AI Deep Dive

Verdict

Locked

The headline call - descriptive label, conviction, and the synthesis behind it.

Company data

Financials